Company intelligence / Profile preview
Shanghai Hansoh Biomedical
Lianyungang, Jiangsu, Chinahspharm.com ↗
- Ownership
- Private
- Employees
- ~12000
- Development stage
- Other
01
Overview
Hansoh Pharma is a leading innovation-driven pharmaceutical company in China with multiple marketed products and a robust clinical pipeline. The company has successfully out-licensed key ADC assets (HS-20093 and HS-20089) to GSK and an oral GLP-1 receptor agonist to Merck (MSD). Its flagship product, Ameile (almonertinib), is a standard-of-care third-generation EGFR TKI in China for NSCLC.
- Therapeutic areas
- EndocrinologyNeurologyDermatologyInfectious DiseasesOncology
- Modalities
- Small moleculeAntibody-drug conjugateMonoclonal antibodysiRNAPeptidesBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
GSKMerck (MSD)Boehringer IngelheimKeros TherapeuticsOliX PharmaceuticalsTiumBioQyuns TherapeuticsBiotheusGlenmark Pharmaceuticals
Beyond the preview
Go deeper on Shanghai Hansoh Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Hansoh Biomedical.